Analyst Price Target is $3.33
▲ +533.71% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Palatin Technologies in the last 3 months. The average price target is $3.33, with a high forecast of $5.00 and a low forecast of $2.00. The average price target represents a 533.71% upside from the last price of $0.53.
Current Consensus is
The current consensus among 3 investment analysts is to buy stock in Palatin Technologies. This Buy consensus rating has held steady for over two years.
Palatin Technologies, Inc. is a biopharmaceutical company, which engages in the development of medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. Its primary product candidate is marketed under the Vyleesi brand, the trade name for bremelanotide, a peptide melanocortin receptor 4 agonist for the treatment of premenopausal women with acquired, generalized, hypoactive sexual desire disorder (HSDD). The company was founded by Carl Spana and John K. A. Prendergast on November 21, 1986 and is headquartered in Cranbury, NJ.